Clinical Trial Update: Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial comparing varying doses of nifekalant for instant cardioversion in persistent atrial fibrillation during radiofrequency ablation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Nifekalant (nifekalant)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Atrial Fibrillation | Phase 4 | Status: UNKNOWN